Department Publications (29)

Peter Gibbs, Volker Heinemann, Navesh K. Sharma, Julien Taieb, Jens Ricke, Marc Peeters, Michael Findlay, Bridget Robinson, Christopher Jackson, Andrew Strickland, Val Gebski, Mark Van Buskirk, Huaqing Zhao, Guy van Hazel: Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. Clinical Colorectal Cancer 06/2018;, DOI:10.1016/j.clcc.2018.06.001

O. Kondrashova, M. Topp, K. Nesic, E. Lieschke, G.Y. Ho, M.I. Harrell, G.V. Zapparoli, A. Hadley, R. Holian, E. Boehm, V. Heong, E. Sanij, R.B. Pearson, J.J. Krais, N. Johnson, O. McNally, S. Ananda, K. Alsop, K.J. Hutt, S.H. Kaufmann, K.K. Lin, T.C. Harding, N. Traficante, A. deFazio, I.A. McNeish, D.D. Bowtell, E.M. Swisher, A. Dobrovic, M.J. Wakefield, C.L. Scott. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nature Comm, December 2018

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Carducci M, Shaheen M, Markman B, Hurvitz S, Mahadevan D, Kotasek D, Goodman OB Jr, Rasmussen E, Chow V, Juan G, Friberg GR, Gamelin E, Vogl FD, Desai J. Invest New Drugs. 2018 Dec;36(6):1060-1071. doi: 10.1007/s10637-018-0625-6. Epub 2018 Jul 7.

Y. Kanjanapan, D. Day, M.O. Butler, L. Wang, A.M. Joshua, D. Hogg, N.B. Leighl, A.R. Abdul Razak, A.R. Hansen, S. Boujos, M. Chappell, K. Chow, B. Sherwin, L-A. Stayner, L. Soultani, A. Zambrana, L. L. Siu, P.L. Bedard, A. Spreafico. Delayed immune-related adverse events in assessment for dose-limiting toxicity in early-phase immunotherapy trials.Eur J Cancer. 2019 Jan;107:1-7. doi: 10.1016/j.ejca.2018.10.017. Epub 2018 Dec 7.

R.B. Cohen, J-P. Delord, T. Doi, S. Piha-Paul, S.V. Liu, J.Gilbert, A. Algazi, S. Damian, R-L. Hong, C. Le Tourneau, D. Day, A. Varga, E. Elez, J. Wallmark, S. Saraf, P. Thanigaimani, J. Cheng, B. Keam. Pembrolizumab for the treatment of advanced salivary gland carcinoma: preliminary findings of the phase 1b KEYNOTE-028 study. American Journal of Clinical Oncology. Nov 2018;41:1083-1088 doi: 10.1097/COC.0000000000000429.

van Leeuwen MT, Luu S, Gurney H, Brown MR, Webber K, Pearson S-A, Hunt L, Vajdic CM. Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews. BMJ Open 2018;8:e021064. doi:10.1136/bmjopen-2017-021064.

Signorelli C, Wakefield C, Johnston K, Fardell J, Brierley, M-E, Thornton-Benko E, Foreman T, Webber K, Wallace H, Cohn R. ‘Re-engage’ pilot study protocol: a nurse-led eHealth intervention to re-engage, educate, and empower childhood cancer survivors. BMJ Open, 2018, 8:e022269. doi:10.1136/bmjopen-2018-022269

Tang M, Webber K. Fertility and pregnancy in cancer survivors. Obstetric Medicine. 2018, 11(3) 110–115. DOI: 10.1177/1753495X18757816

MacIntyre CR., Costantino V, Chen X, Segelov E, Chughtai, A, Kelleher A, Kunasekaran, M, Lane JM. 2018. Influence of population immunosuppression and past vaccination on smallpox reemergence. Emerging Infectious Diseases. 24:4:646-653.

Chin-Lenn L, Segelov E, De Boer RH, Marx GM, Hughes TM, McCarthy NJ, White S, Foo SS, Rutovitz JJ, Della-Fiorentina S, Jennens R, Antill YC, Tsoi D, Cronk MF, Lombard JM, Kiely BE, Chirgwin JH, Mann B. 2018. “The impact and indications for Oncotype DX on adjuvant treatment recommendations when third‐party funding is unavailable.” Asia‐Pacific Journal of Clinical Oncology (2018).

Shapiro, S. Thayaneswaran, C. Underhill, K. Robledo, C. Karapetis, F. Day, L. Nott, J. Jefford, L. Chantrill, N. Pavlakis, N. Tebbutt, T. Price, M. Khasraw, G. V. Hazel, P. Waring, S. Tejpar, J. Simes, V. Gebski, J. Desai, E. Segelov. Cetuximab alone or with irinotecan for refractory KRAS-, NRAS-, BRAF- and PIK3CA-wild-type metastatic colorectal cancer: the AGITG randomised phase II ICECREAM study. Clinical Colorectal Cancer, 2018, Jun 8.

Singh S, Moody L, Chan D, Metz D, Strosberg J, Asmis T, Bailey D, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan S, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E. Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours. JAMA Oncology(2018) July 26.

Tang M, Price T, Shapiro J, Gibbs P, Haller D, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. 2018. Targeted therapies for metastatic colorectal cancer. Expert Review in Anticancer Therapy 18.10(2018): 991-1006

Tang M, Price JT, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis (2018). Expert Review of Anticancer Therapy. Volume 18(4), 339-349.

Singh S, Chan DL, Moody L, Liu N, Fischer HD, Austin PC, Segelov E. Recurrence in Resectable Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018;4(4): 583-585.

Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis P, Boyle F, Friedlander M. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. Br J Cancer 2018. In Press

Ha FJ, Spain L, Dowling A, Kwan EM, Pezaro C, Day D, Chia PL, Tran B, Pook D, Weickhardt AJ. Timing of Brain Metastases Development in Metastatic Renal Cell Cancer patients treated with Targeted Therapies and Survival Outcomes: an Australian Multicentre Study. Asia Pac J Clin Oncol 2018. In Press

Fettke HC*, Kwan EM*, Azad AA. Cell-free DNA in cancer: current insights. Cell Oncol (Dordr). In Press * Co-first author

C. J. McLaren., D. Day., D Croagh., A. Strickland., E. Segelov: Endoscopic Ultrasound in Pancreatic Cancer. Advances in Pancreatic Cancer, 09/2018; , ISBN: 978-1-78923-640-8, DOI:10.5772/intechopen.75211

P. Gibbs., V. Heinemann., N. K. Sharma., J. Taieb., J. Ricke., M. Peeters., M. Findlay., B. Robinson., C. Jackson., A. Strickland., V. Gebski., M. Van Buskirk., H. Zhao., G. Van Hazel: Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. Clinical Colorectal Cancer 06/2018;, DOI:10.1016/j.clcc.2018.06.001

K. Shitara., M. Özgüroğlu., Y. Bang., M. Di Bartolomeo., M. Mandalà., M. Ryu., L. Fornaro., T. Olesiński., C. Caglevic., H. C Chung., K. Muro., E. Goekkurt., W. Mansoor., R. S McDermott., E. Shacham-Shmueli., X. Chen., C. Mayo., S. P. Kang., A. Ohtsu., C. S Fuchs., G. Lerzo., J. M. O’Connor., G. A. Mendez., J. Lynam., N. Tebbutt., M. Wong., A. Strickland., et al: Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. The Lancet 06/2018; 392(10142)

M. G. Lawrence., D. Obinata., S. Sandhu., L. A. Selth., S. Q. Wong., L. H. Porter., N. Lister., D. Pook., et al. Patient-derived models of abiraterone-and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy. European urology 74 (5), 562-572 (2018)

Sarah Q. To, Edmond M. Kwan, Heidi C. Fettke, Andrew Mant, Maria M. Docanto, Luciano Martelotto, Patricia Bukczynska, Nicole Ng, Lisa-Jane K. Graham, Phillip Parente, Carmel Pezaro, Kate Mahon, Lisa Horvath, Tilman Todenho¨fer, Arun A. Azad. Expression of Androgen Receptor Splice Variant 7 or 9 in WholeBlood Does Not Predict Response to Androgen-Axis–targeting Agents in Metastatic Castration-resistant Prostate Cancer Eur Urol 2018. doi: 10.1016/j.eururo.2018.01.007. [Epub ahead of print]

Au L, Grant M, Haydon A, Segelov E, Antill Y, Oliva, Wilkins S, P McMurrick P, J Shapiro J. 2018. Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: a cohort study of two cancer centres. International Journal of Surgery. 51:71-5.

Chi, W, Warner R, Chan D, Singh S, Segelov E, Strosberg J, Wisnivesky J, Kim M. 2018. Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors. Pancreas. 47:321-25.

Chan DL, Moody L, Segelov E, Metz D, Strosberg J, Pavlakis N, Singh S. Follow-up for resected gastroenteropancreatic neuroendocrine tumours (GEP-NETs): A practice survey of the Commonwealth Neuroendocrine collaboration (CommNETs) and the North American Neuroendocrine Tumor Society (NANETS). Neuroendocrinology, 2018.

S. R. Davis., P. J. Robinson., F. Jane., S. White., M. White., R. J. Bell. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors. The Journal of Clinical Endocrinology & Metabolism. November 2018, Volume 103(11), 4146-4154.

K. D. Marini., D. R. Croucher., R. A. McCloy., V. Vaghjiani, A. Gonzalez-Rajal, J. F. Hastings, V. Chin, A. Szczepny, K. Kostyrko, C. Marquez, W. S. N. Jayasekara., M. Alamgeer., V. Boolell., J. Z. R. Han., T. Waugh., H. C. Lee., S. R. Oakes., B. Kumar., C. A. Harrison., M. P. Hedger., N. Lorensuhewa., B. Kita., R. Barrow., B. W. Robinson., D. M. de Kretser, J. Wu., V. Ganju, E. A. Sweet-Cordero, A. Burgress, L. G. Martelotto, F. J. Rossello, J. E. Cain, D. N. Watkins. Inhibition of activing signalling in lung adenocarcinoma increase the therapeutic index of platinum chemotherapy. Sci Transl Med (10), 2018.

T. L. Leong., V. Gayevskiy., D. P. Steinfort., M. R. De Massy., A. Gonzalez-Rajal., K. D. Marini., E. Stone., V. Chin., A. Havryk., M. Plit., L. B. Irving., B. R. Jennings., R. A. McCloy., W. S. N. Jayasekara., M. Alamgeer., V. Boolell., A. Field., P. A. Russell, B. Kumar., D. J. Gough., A. Szczepny., V. Ganju., F. J. Rossello., J. E. Cain., A. T. Papenfuss., M. Asselin-Labat., M. J. Cowley., D. N. Watkins. Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naïve, metastatic lung cancer. Oncogene, 2018

 

Department Abstracts (34)

Implementation of a decision support triage tool in specialist-general practitioner shared care. / Lewis, John; Vuong, K.; Webber, K.; Taggart, J.; Jun, S.; Uebel, K.; Agaliotis, M.; Liauw, W.; Harris, M. 2018. Abstract from Sydney Cancer Conference 2018, Sydney, Australia.

“Re-engage”: Promoting engagement and empowering childhood cancer survivors through a new nurse-led ehealth intervention. / Signorelli, C.; Wakefield, C.; Johnston, K.; Fardell, J.; Brierley, M-E.; Thornton-Benko, E.; Foreman, T.; Webber, K.; Wallace, H.; Cohn, R. In: Psycho-Oncology, Vol. 27, No. Supplement 3, 689, 01.10.2018, p. 194-195.

When will I feel normal again? Exploring the trajectories and predictors of patient-reported outcomes after completion of primary therapy for ovarian cancer. / Beesley, V.L.; Webber, K.; Nagle, C.; Grant, P.; DeFazio, A.; Obermair, A.; Friedlander, Michael L.; Webb, P.M. Psycho-oncology. Vol. 27 2018. p. 50.

Kwan EM, Semira M, Muttiah C, Beck S, Anton A, Tran B. Changing treatment landscape in the initial management of metastatic castrate-resistant prostate cancer (mCRPC): an Australian multi-centre retrospective study, Oral Abstract Presentation, MOGA Annual Scientific Meeting, 2018. Adelaide, Australia.

Fettke HC, Kwan EM, Mant A, Docanto MM, Bukczynska P, To SQ, Waltham M, Ng N, Parente P, Pezaro C, Azad AA. Plasma cell-free DNA concentration and outcomes in metastatic castrate-resistant prostate cancer patients treated with androgen receptor signalling inhibitors, Oral Abstract Presentation, ANZUP Annual Scientific Meeting, 2018. Sydney, Australia. * Selected for “Best of the Best” session

D. Day, J. Gruner, G. Young, S. Frentzas, B. Markman, M. Green, E. Segelov. Prospective characterisation of a novel circulating tumour-derived DNA (ctDNA) methylation assay to monitor tumour burden and response to therapy in metastatic colorectal cancer (CATCHER-1). AGITG Annual Scientific Meeting and Monash Health Translation Precinct Research Symposium 2018.

C. Lum, S. Rogers, K. Sharma, L. Marshall, S. Sherwell, M. Franco, A.M. Hadley, E. Segelov, D. Day. Implementation and results of the Victorian Cancer Patient Experience Survey (VCPES) at Monash Health.  COSA Annual Scientific Meeting 2018.

Y. Kanjanapan, D. Day, Lisa Wang, A.R. Hansen, A.A. Razak, A. Spreafico, N. Leighl, A.M. Joshua, M. Butler, D. Hogg, L.L. Siu, P.L. Bedard. Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials. ASCO Annual Meeting 2018

Rao, S., Sclafani, F., Eng, C., Grønlie Guren, M., Adams, R.A., Benson, A., Sebag-Montefiore, D., Segelov E, Bryant, A., Peckitt, C. and Roy, A., 2018. LBA21 InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease-An International Rare Cancers Initiative (IRCI) trial. Annals of Oncology, 29(suppl_8), pp.mdy424-022

La C, Segelov E, McLeod V, Grewal G. An expanded role oncology pharmacist adds value to symptom and urgent review clinics. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. Vol. 14. 2018.

Gan C, Gruner J, Segelov E.  Survey on patterns of travel for patients attending chemotherapy day units in Monash Health-A local experience. .ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. Vol. 14. p113, 2018.

Lie G, Segelov E, Srivastava R. Implementation of a validated chemotherapy prediction tool in a busy oncology clinic. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 2018 Nov 1 Vol. 14, pp. 118-119).

Lum C, Rogers S, Sharma K, Marshall L, Sherwell S, Franco M, Hadley AM,  Segelov E, Day D. Implementation and results of the Victorian cancer patient experience survey (VCPES) at Monash Health. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 2018 Nov 1 Vol. 14, pp. 119-119

Blinman P, Martin A, Jefford M, Goldstein D, Boadle D, Morris M, Tebbutt N, Aiken C, Segelov E, Paul J, Haydon A. Patients’ Preferences for 3 Versus 6 Months of Adjuvant Chemotherapy (ACT) for Colon Cancer in the SCOT Trial: What Survival Benefits Make Longer Chemotherapy Worthwhile? ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 2018 Aug 1 Vol. 14, pp. 51-51.

Super L, Nguyen H, Segelov E, McLeod V, Degraves S, Fedele P, Vandenberg K, James K. A Pathway to Improving an Adolescent and Young Adult Oncology Service: Voices of Patients and Parents. 3rd Global Adolescent & Young Adult Cancer Congress. Dec 2018, Sydney.

Segelov E, Bergsland E, Card C, Hope T, Kunz P, Laidley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer  A, Wei B, Xu B,  Singh S. 2018. Pulmonary Neuroendocrine (Carcinoid) Tumors: The Commonwealth Neuroendocrine Tumour Collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS) Endorsement and Update of European Neuroendocrine Tumor Society (ENETS) Best Practice Consensus for Lung Neuroendocrine Tumors (LNET), Annals of Oncology. 2018 Oct 1;29(suppl 8).

Rao, S., Sclafani, F., Eng, C., Grønlie Guren, M., Adams, R.A., Benson, A., Sebag-Montefiore, D., Segelov E, Bryant, A., Peckitt, C. and Roy, A., 2018. LBA21 InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease-An International Rare Cancers Initiative (IRCI) trial. Annals of Oncology, 29(suppl_8), pp.mdy424-022.

Singh, S., Bergsland, E., Card, C., Hope, T., Kunz, P., Laidley, D., Lawrence, B., Leyden, S., Michael, M., Modahl, L. and Myrehaug, S., Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, Segelov E. 2018. P1. 12-06 Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus. Journal of Thoracic Oncology, 13(10), p.S575.

La C, Segelov E, McLeod V, Grewal G. An expanded role oncology pharmacist adds value to symptom and urgent review clinics. Accepted for COSA 2018 Nov, Perth.

Gan C, Gruner J, Segelov E. Survey on patterns of travel for patients attending chemotherapy day units in Monash Health- a local experience. Accepted for COSA 2018 Nov, Perth.

Super L, Nguyen H, Segelov E, McLeod V, Degraves S, Fedele P, Vandenberg K, James K. A Pathway to Improving an Adolescent and Young Adult Oncology Service: Voices of Patients and Parents. Accepted for 3rd Global Adolescent & Young Adult Cancer Congress. Dec 2018, Sydney.

Segelov E, Williams D, Chia J, Sieber O. COX2 and HLA immunohistochemical (IHC) staining in colorectal tumour samples from patients participating in the ASCOLT clinical trial of adjuvant aspirin therapy. Journal Clinical Onc 36 (4_suppl), 695-695.

Clarke S, Burge M, Feeney K, Jones K, Gibbs P, Molloy M,Marx G, Price T, Reece W, Segelov E, Tebbutt N. Results from an Australian translational study to evaluate the prognostic role of inflammatory markers in patients with mCRC treated with bevacizumab. Journal Clinical Onc 36 (4_suppl), 719-719. Presented at ASCO GI 2018.

Blinman, D. Goldstein, A. Martin, M. Jefford, D. Boadle, N. Tebbutt, J. Paul, A. Haydon, E. Segelov, M. Stockler. Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile? J Clin Oncol (2018) 36:15_suppl: 3602-3602.

Singh S, Bergsland E, Card C, Hope T, Kunz P, Ladiley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, Segelov E. Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus, IASLC 19th World Conference on Lung Cancer Sept 2018, Toronto.

Segelov E, Bergsland E, Card C, Hope T, Kunz P, Ladiley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, Singh S. Pulmonary Neuroendocrine (Carcinoid) Tumors: The Commonwealth Neuroendocrine Tumour Collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS) Endorsement and Update of European Neuroendocrine Tumor Society (ENETS) Best Practice Consensus for Lung Neuroendocrine Tumors (LNET), European Society of Medical Oncology, Oct 2018, Munich.

M. Alamgeer., D. N. Watkins., I. Banakh., B. Kumar., D. J. Gough., B. Markman., Vinod Ganju. A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer. Investigational New Drugs (2018) 36:288-298

Kwan EM, Semira M, Muttiah C, Beck S, Anton A, Tran B. Changing treatment landscape in the initial management of metastatic castrate-resistant prostate cancer (mCRPC): an Australian multi-centre retrospective study, Oral Abstract Presentation, MOGA Annual Scientific Meeting, 2018. Adelaide, Australia.

Fettke HC, Kwan EM, Mant A, Docanto MM, Bukczynska P, To SQ, Waltham M, Ng N, Parente P, Pezaro C, Azad AA. Plasma cell-free DNA concentration and outcomes in metastatic castrate-resistant prostate cancer patients treated with androgen receptor signalling inhibitors, Oral Abstract Presentation, ANZUP Annual Scientific Meeting, 2018. Sydney, Australia. * Selected for “Best of the Best” session

Kwan EM, To SQ, Fettke HC, Mant A, Docanto MM, Martelotto L, Bukczynska P, Ng N, Graham LK, Parente P, Pezaro C, Mahon K, Horvath L, Todenhofer T, Azad AA. Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer, Poster Presentation, ASCO GU, 2018. San Francisco, USA. * Conquer Cancer Foundation Merit Award

L. Gulley, M. Borre, N. J. Vogelzang, S. Ng, N. Agarwal, C. C. Parker, D. W. Pook, P. Rathenborg, T. W. Flaig, J. Carles, N. D. Shore, L. Chen, C. R. Heery, W. R. Gerritsen, F. Priou, P. W. Kantoff. Results of PROSPECT: A randomized phase 3 of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. J Clin Oncol (2018) 36:15_suppl, 5006-5006.

Michael, D. W. Pook, V. Ganju, E. Link, G. C. Toner, R. J. Hicks, A. Matera, M. Thompson, C. Cullinane, I. Campbell, M. Burge, C. S. Karapetis. The utility of genomics and functional imaging to predict Sunitinib PK and PD: The Predict SU study. J Clin Oncol 36, 2018 (suppl; abstr 2563).

Desai, M. Voskoboynik, B. Markman, J. Hou, D. Zeng, T. Meniawy. Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclona antibody bgb-A333 alone and in combination with anti-PD-monoclonal antibody tislelizumab in patients with advanced solid tumors. J Clin Oncol 36, 2018 (suppl; abstr TPS3113).

Get the latest information about coronavirus (COVID-19).Find out more
+